Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Giamarellos Bourboulis, Evangelos J ^a   Norrby Teglund, Anna ^b   Mylona, Vassiliki ^c   Savva, Athina ^a   Tsangaris, Iraklis ^a   Dimopoulou, Ioanna ^a   Mouktaroudi, Maria ^a   Raftogiannis, Maria ^a   Georgitsi, Marianna ^a   Linnér, Anna ^b   Adamis, George ^d   Antonopoulou, Anastasia ^a   Apostolidou, Efterpi ^e   Chrisofos, Michael ^a   Katsenos, Chrisostomos ^f   Koutelidakis, Ioannis ^g   Kotzampassi, Katerina ^g   Koratzanis, George ^c   Koupetori, Marina ^h   Kritselis, Ioannis ⁱ   Lymberopoulou, Korina ^c   Mandragos, Konstantinos ^f   Marioli, Androniki ^c   Sundén Cullberg, Jonas ^b   Mega, Anna ^j   Prekates, Athanassios ^k   Routsi, Christina ^a   Gogos, Charalambos ^l   Treutiger, Carl Johan ^b   Armaganidis, Apostolos ^a   Dimopoulos, George ^a   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAROLINSKA INSTITUTE   (Sweden)

^c 'Sismanogleion' Athens Hospital   (Greece)

^d 'G Gennimatas' Athens Hospital   (Greece)

^e Ptolemaida General Hospital   (Greece)

^f Intensive Care Unit   (Greece)

^g ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^h 'Thriassio' Elefsina General Hospital   (Greece)

ⁱ Nafplion General Hospital   (Greece)

^j LAIKO GENERAL HOSPITAL   (Greece)

^k TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^l UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; AGED; APACHE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SWEDEN; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; GREECE; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; REGRESSION ANALYSIS; SHOCK, SEPTIC;

APACHE; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; GREECE; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; SEPSIS; SHOCK, SEPTIC; SWEDEN;

EID: 84864541602     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11463     Document Type: Article

References (26)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
2. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
3. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:23-31. 10.1097/01.qai.0000157950.02076.a6, 15851910.
4. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96:4091-4095.
5. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27:157-172.
6. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, 270:32-40. 10.1111/j.1365-2796.2011.02363.x, 21332843.
7. Koch A, Voigt S, Kruschinski C, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15:R63. 10.1186/cc10037, 3221996, 21324198.
8. Hellenic Sepsis Study Group homepage. , http://www.sepsis.gr
9. Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
10. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am J Resp Crit Care Med 2006, 174:84-93. 10.1164/rccm.200512-1922OC, 16603606.
11. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
12. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, Correa H, Diaz E, Garnacho J, Llorio M, Rios M, Rodriguez A, Solé-Violán J. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001, 120:955-970. 10.1378/chest.120.3.955, 11555535.
13. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB. Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-151. 10.1016/S0735-6757(97)90087-5, 9115515.
14. Calandra T, Cohen J. The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 2005, 33:1639-1648.
15. Sundén-Cullberg J, Nyström T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 2007, 35:1536-1542. 10.1097/01.CCM.0000266536.14736.03, 17452927.
16. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573. 10.1097/01.CCM.0000155991.88802.4D, 15753748.
17. Linder A, Akesson P, Inghammar M, Treutiger CJ, Linner A, Sunden-Cullberg J. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit Care 2012, 16:R90. 10.1186/cc11353, 22613179.
18. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872, 2875530, 20144219.
19. Cook NR. Methods for evaluating novel biomarkers- a new paradigm. In t J Clin Pract 2010, 64:1723-1727.
20. Pratikaki M, Platsouka E, Sotiropoulou C, Vassilakopoulos T, Paniara O, Roussos C, Routsi C. Risk factors for and influence of bloodstream infections on mortality: a 1-year prospective study in a Greek intensive-care unit. Epidemiol Infect 2009, 137:727-735. 10.1017/S0950268808001271, 18796170.
21. Markogiannakis H, Pachylaki N, Samara E, Kalderi M, Minettou M, Toutouza M, Toutouzas KG, Theodorou T, Katsaragakis S. Infections in a surgical intensive care unit of a university hospital in Greece. Int J Infect Dis 2009, 13:145-153. 10.1016/j.ijid.2008.05.1227, 18775663.
22. Jacobson S, Johansson G, Winsö O. Primary sepsis in a university hospital in northern Sweden: a retrospective study. Acta Anaesthesiol Scand 2004, 48:960-967. 10.1111/j.0001-5172.2004.00458.x, 15315612.
23. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52:1284-1293. 10.1373/clinchem.2006.067595, 16690735.
24. Rabna P, Andersen A, Wejse C, Oliveira I, Francisco Gomes V, Bonde Haaland M, Aaby P, Eugen-Olsen J. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation 2010, 33:374-380. 10.1007/s10753-010-9195-2, 20229356.
25. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60. 10.1007/s00134-007-0934-2, 2249616, 18058085.
26. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med 2010, 38:283-287. 10.1097/CCM.0b013e3181b785a2, 19730252.